Last reviewed · How we verify
Beta blocker, aspirin, clopidogrel
This is a combination therapy that reduces heart rate and blood pressure (beta blocker) while inhibiting platelet aggregation and clot formation (aspirin and clopidogrel) to prevent cardiovascular events.
This is a combination therapy that reduces heart rate and blood pressure (beta blocker) while inhibiting platelet aggregation and clot formation (aspirin and clopidogrel) to prevent cardiovascular events. Used for Acute coronary syndrome, Secondary prevention after myocardial infarction, Prevention of stent thrombosis.
At a glance
| Generic name | Beta blocker, aspirin, clopidogrel |
|---|---|
| Also known as | Beta-blockers, Aspirin, Clopidogrel |
| Sponsor | Spanish Society of Cardiology |
| Drug class | Combination antithrombotic and antihypertensive therapy |
| Target | Beta-adrenergic receptors; COX-1; P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Beta blockers work by blocking beta-adrenergic receptors to decrease heart rate, contractility, and blood pressure. Aspirin irreversibly inhibits cyclooxygenase (COX) to prevent thromboxane A2 production and platelet aggregation. Clopidogrel is a P2Y12 receptor antagonist that prevents ADP-induced platelet activation. Together, these agents reduce the risk of myocardial infarction, stent thrombosis, and stroke in cardiovascular disease.
Approved indications
- Acute coronary syndrome
- Secondary prevention after myocardial infarction
- Prevention of stent thrombosis
- Stroke prevention in cardiovascular disease
Common side effects
- Bleeding
- Bradycardia
- Fatigue
- Dyspnea
- Gastrointestinal bleeding
- Hypotension
Key clinical trials
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction (NA)
- Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection (PHASE4)
- Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions (NA)
- Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes (NA)
- The Success of Opening Concurrent CTO leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease
- Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |